Combating ESKAPE Pathogens Using Biotherapeutic Agents
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 192
Special Issue Editor
Interests: outer membrane vesicles; antibiotic resistance; vaccines; communication; biofilm formation
Special Issue Information
Dear Colleagues,
Through a combination of global stewardship and sentry antimicrobial surveillance programs, a decrease in the prevalence of several ESKAPE pathogens has been reported over the last decade. In addition, the encapsulation of antibiotics in antimicrobial nanovehicles and repotentiation via novel combinatorial therapies have improved pharmacokinetic profiles and reduced adverse effects on the host. However, many of these programs were suspended for most of the COVID-19 pandemic and biocidal usage was enhanced—the former known to contribute to AMR resistance.
In addition, many of these ESKAPE pathogens can share resistance mechanisms if exposed to sub-lethal antibiotic concentrations via outer membrane vesicle (OMV) exchange. OMVs have been shown to hijack the host's immune response, prolong infection, and reduce vaccine efficacy.
This Special Issue aims to encourage original articles addressing developments in OMV diagnostics, vaccination strategies, biocompatible delivery vehicles, and the molecular mechanisms underlying antibiotic resistance for discovering novel therapeutics. Thus, we are pleased to invite colleagues to contribute original articles and reviews.
I look forward to receiving your contributions.
Dr. John P. Hulme
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimicrobial resistance
- virulence
- beta-lactamase
- ESKAPE pathogens
- biotherapeutic agents
- antibacterial agent
- drug tolerance
- vancomycin
- biofilm
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
